CING Cingulate Inc.

$5.09

Cingulate Inc. (CING) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.6% since its last earnings release on August 13, 2026.

Cingulate Beat Consensus Estimates
Thursday, August 13, 2026 · 8:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($0.56)
Rev est $2.68M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.04

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cingulate Inc.

Cingulate Inc. is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

Sector

Healthcare

Industry

Biotechnology